Ieni Antonio, Vita Roberto, Magliolo Emilia, Santarpia Mariacarmela, Di Bari Flavia, Benvenga Salvatore, Tuccari Giovanni
Department of Human Pathology of Adult and Evolutive Age "Gaetano Barresi"-Section of Pathological Anatomy, University of Messina, Messina, Italy.
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Front Endocrinol (Lausanne). 2017 Dec 1;8:337. doi: 10.3389/fendo.2017.00337. eCollection 2017.
The significance and impact of the coexistence of chronic lymphocytic thyroiditis (CLT) with thyroid cancer is still debated. To verify the influence of CLT on papillary thyroid cancer (PTC), we retrospectively collected 505 PTC cases and analyzed age at diagnosis, sex, size, lymph node status, and staging. We found that CLT was present in 168 PTC (33.3%). Compared with the 337 patients without CLT (non-CLT), CLT patients were younger (44.42 ± 13.72 vs. 47.21 ± 13.76 years, = 0.03), had smaller tumors (9.39 ± 6.10 vs. 12 ± 9.71 mm, = 0.002), and lower rate of lymph node metastases (12.5 vs. 21.96%, = 0.01, OR = 0.508). Tumor-node-metastasis (TNM) staging (T1a through T4) was more favorable for the CLT group compared to the non-CLT group (for instance, T1a = 65.5 vs. 49.8%, T3 = 4.8 vs. 23.4%). This study shows that one in three patients with PTC harbors CLT, which is associated with a more favorable TNM staging, consistently with a favorable outlook of PTC.
慢性淋巴细胞性甲状腺炎（CLT）与甲状腺癌并存的意义和影响仍存在争议。为了验证CLT对甲状腺乳头状癌（PTC）的影响，我们回顾性收集了505例PTC病例，并分析了诊断时的年龄、性别、肿瘤大小、淋巴结状态和分期。我们发现168例PTC（33.3%）存在CLT。与337例无CLT（非CLT）患者相比，CLT患者更年轻（44.42±13.72岁 vs. 47.21±13.76岁，P = 0.03），肿瘤更小（9.39±6.10 mm vs. 12±9.71 mm，P = 0.002），淋巴结转移率更低（12.5% vs. 21.96%，P = 0.01，OR = 0.508）。与非CLT组相比，CLT组的肿瘤-淋巴结-转移（TNM）分期（T1a至T4）更有利（例如，T1a = 65.5% vs. 49.8%，T3 = 4.8% vs. 23.4%）。本研究表明，三分之一的PTC患者患有CLT，这与更有利的TNM分期相关，与PTC的良好预后一致。
